Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

  • In development
  • GID-TA11023
  • Expected publication date: TBC
The second committee meeting for this topic has now been scheduled for Wednesday 13 August 2025. This is to ensure Johnson & Johnson Innovative Medicine and all other stakeholders have sufficient time to review the Draft Guidance and provide the full evidence needed to inform the committee’s recommendations